Mr. Foletta was announced as Executive Vice President and Chief Financial Officer of Tocagen in March 2017. He holds more than 30 years of experience in finance and accounting. Prior to joining Tocagen, Mr. Foletta was the Chief Financial Officer of Amylin Pharmaceuticals, Inc. from April 2000 until Amylin’s acquisition by Bristol-Myers Squibb Company in October 2012. He served as Senior Vice President, Finance and Chief Financial Officer from March 2006 until October 2012, and as Vice President, Finance and Chief Financial Officer from March 2000 to March 2006. Mr. Foletta has also held a number of management positions from 1986-2000 with Intermark, Inc. and Triton Group Ltd., and from 1982-1986 worked for Ernst & Young, leaving as an Audit Manager. Mr. Foletta currently serves on the Board of Directors and is Chairman of the Audit Committees of AMN Healthcare Services, Dexcom, Inc., and Regulus Therapeutics, Inc. Previously, Mr. Foletta served as a member of the Board of Directors and Audit Committee Chairman for Ambit Biosciences Corporation, now owned by Daiichi Sankyo Company, Limited, and Anadys Pharmaceuticals, Inc., now owned by F. Hoffman La-Roche Ltd.. Mr. Foletta received a bachelor’s degree in business economics from the University of California, Santa Barbara. He is a Certified Public Accountant (inactive) and a member of the Corporate Directors Forum.